Johnson & Johnson's Shockwave Javelin Coronary IVL Catheter Shows Positive 30-Day Results in Pivotal FORWARD CAD IDE Study

Johnson & Johnson announced positive 30-day results from the FORWARD coronary artery disease (CAD) investigational device exemption (IDE) study for its Shockwave Javelin Coronary Intravascular Lithotripsy (IVL) Catheter. The study, presented at the 2026 Transcatheter Cardiovascular Therapeutics (TCT) congress, demonstrated a 93.6% technical success rate and 93.4% freedom from major adverse cardiovascular events through 30 days in patients with calcified coronary artery lesions. These findings suggest a significant step towards improving treatment options for complex calcified lesions prior to stenting.